Myriad Genetics, Inc.
Myriad Genetics is a molecular diagnostics company with minimal political/regulatory footprint and low government revenue dependence.
BusinessWhat MYGN does
Myriad Genetics develops and commercializes molecular diagnostic tests, primarily in oncology, women's health, and mental health. Revenue derives from direct-to-consumer and healthcare-provider diagnostic testing, with limited Medicare/Medicaid reimbursement exposure relative to larger pharma.
Executive Branch ConflictsMYGN held by Trump-administration officials
Lifetime Government AwardsMYGN federal contracts by year
Smart Money · 13F HoldingsHedge funds holding MYGN
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
Stock awards & option exercises
Bills to WatchLegislation flagged by our analysis
Political ProfileWhere MYGN sits in Washington
Myriad has minimal lobbying spend, no documented politician trades, and no named legislative winners/losers. Stock movement driven primarily by clinical trial results, reimbursement decisions, and competitive diagnostics landscape rather than federal policy.
Regulatory ExposureThreats & opportunities
Regulatory threats
- CMS LCD/NCD reimbursement cuts
- FDA oversight of LDTs (Laboratory Developed Tests)
Regulatory opportunities
- CMS coverage expansion for genetic testing
- FDA streamlined approval pathways for companion diagnostics
LobbyingWho's hired to advocate for MYGN
Live signals + predictions for MYGN — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades MYGN
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord